Skip to content

MPN-MDS

EU Focus Meeting 2026


📍 Courtyard by Marriott Vienna Prater/Messe, Trabrennstrasse 4, Vienna, Austria, 1020

🗓️ September 23 - 24, 2026


Last Year's Highlights

Dear Colleagues and Friends,

We are delighted to extend our warmest invitation to the MPN-MDS Focus Meeting 2026, to be held on September 23 - 24, 2026.  

Centered around the theme “Updating Knowledge & Clinical Practice in 2026” this meeting provides pivotal collaboration aimed at advancing MPN-MDS research and patient treatment.  

This meeting presents an opportunity for medical professionals to engage in the exchange of knowledge, expertise, and insights, as well as networking with leading experts. Engage in riveting presentations, participate in thought-provoking debates and roundtable discussions, and connect with peers at informal social gatherings.

Chairs of MPN-MDS EU Focus Meeting 2026:

Rami-Komrokji

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL


Alessandro-Vannucchi

Dr. Alessandro M. Vannucchi
University of Florence, Italy


Supporters to be announced...
Interested in supporting this meeting? Get in contact:
ben.whitley@md-education.com

Agenda & Faculty

October 23, 2026 | Day 1  

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Coffee Break

Session I: Pathophysiology of MPN and MDS
Moderated by: TBD

09:05 AM
Targeting Hepcidin in MPN (PV and MF)

TBD

KOL TBD
TBD

09:25 AM
JAK2 Mutated Specific Inhibitor(s): Dream or Realty?

SC

Stefan Constantinescu, MD
Université catholique de Louvain, Belgium

09:45 AM
Special Interest Lecture: The JAK2 46/1, and Other Predisposition Haplotypes for MPN, Revisited

NC

Nick Cross, MD
University of Southampton, UK

10:05 AM
Panel Discussion
10:25 AM
Coffee Break

Session II: Debates in MPN
Moderated by: TBD

Debate 1: Is Two Better Than One: Combination Therapies in MF

10:45 AM
Yes

CH

Claire Harrison, MD
Guy’s and St Thomas’ NHS Foundation Trust, London, UK

11:05 AM
No

FP

Francesco Passamonti, MD
University of Milan, Italy

Debate 1: Splancnic Vein Thrombosis in MPN: Cytoreduction is Needed

11:25 AM
Yes

TBD

KOL TBD
TBD

11:45 AM
No

DL

Danijela Lekovic, MD
University Clinical Center Serbia, Belgrade, Serbia

12:05 PM
Panel Discussion
12:25 PM
Lunch Break + Faculty and Fellow Photo
01:15 PM
Industry Supported Independent Expert Discussion

Session III: Essential Thrombocythemia and Special Situation
Moderated by: TBD

02:00 PM
Evidence-Based Management of Essential Thrombocythemia in 2026

AG

Anna Godfrey, MD
Cambridge University Hospitals NHS Foundation Trust, UK

02:20 PM
Novel Drugs for ET (I): Interferon, Bomedestat, CALR Immunotherapies

JK

Jean-Jacques Kiladjian, MD
Hospital Saint-Louis AP-HP, Paris, France

02:40 PM
Recommendations for Female Gender-Related Management Issues in MPN

MG

Martin Griesshammer, MD
Johannes Wesling Medical Center Minden, Germany

03:00 PM
Panel Discussion
03:20 PM
Coffee Break
03:40 PM
Industry Supported Independent Expert Discussion

Session IV: Management Issues in Myekofibrosis
Moderated by: TBD

04:25 PM
Management of Anemia in MF

PG

Paola Guglielmelli, MD
University of Florence, Italy

04:45 PM
Management of JAKi Side Effects in MPN

IU

Ivana Urosevic, MD
University of Novi Sad, Serbia

05:05 PM
Management of Transplantation in MF

JH

Juan-Carlos
Hernandez-Boluda, MD
University of Valencia, Spain

05:25 PM
Panel Discussion
05:45 PM
Special Interest Lecture: MPN-Blast phase: are we making progress?

AV

Alessandro M.  Vannucchi, MD
University of Florence, Italy

06:05 PM
Adjourn

October 24, 2026 | Day 2

07:00 AM
Registration Opens
08:00 AM
Industry Supported Independent Expert Discussion
08:45 AM
Coffee Break

Session V: Less Common MPNs: Updates on Diagnosis and Treatment
Moderated by: TBD

09:05 AM
Aggressive Systemic Mastocytosis

AR

Andreas Reiter, MD
University Medical Centre Mannheim, Germany

09:25 AM
Rare Myeloprolifereative Neoplasia with Eosinophilia

TBD

TBD
TBD

09:45 AM
Blastic Plasmocytoid Dendritic Cell Neoplasm (BDPCN)

TBD

TBD
TBD

10:05 AM
Panel Discussion
10:25 AM
Coffee Break

Session VI: TBD
Moderated by: TBD

10:45 AM
MPN in the Youngest

JI

Jean-Christophe Ianotto, MD
Centre Hospitalier Universitaire de Brest, France

11:05 AM
Addressing Optimal Symptom Management in MPN in Clinical Practice

GC

Giovanni Caocci, MD
University of Cagliari, Italy

11:25 AM
Treatment endpoints for CML in 2026

MB

Massimo Breccia, MD
Sapienza University of Rome, Italy

11:45 AM
Panel Discussion
12:05 PM
Special Interest Lecture: TP53 Myeloid Neoplasms

TBD

TBD
TBD

12:25 PM
Lunch Break
01:15 PM
Industry Supported Independent Expert Discussion

Session VII: Debate in Myelodysplastic Syndrome
Moderated by: TBD

Debate 1: When to Treat Anemia in Lower Risk MDS
02:00 PM
I Treat Non-RBC-TD Anemia

KG

Katharina Goetze, MD
Klinikum Rechts der Isar, Technical University Munich, Germany

02:20 PM
I Treat Only RBC-TD Anemia

MS

Marie Sebert, MD
Hospital Saint-Louis AP-HP, Paris, France

Debate 2: Venetoclax in HR MDS
02:40 PM
Venetoclax is Dead in HRMDS After VERONA Study Results

VS

Valeria Santini, MD
University of Florence Medical School, Italy

03:00 PM
Venetoclax is Still Alive in HRMDS

LA

Lionel Ades, MD
Hospital Saint-Louis AP-HP, Paris, France

03:20 PM
Panel Discussion
03:40 PM
Coffee Break
04:00 PM
Industry Supported Independent Expert Discussion

Session VIII: MDS
Moderated by: TBD

04:45 PM
How do I Treat Lower Risk MDS?

MDC

Maria Diez Campelo, MD
University of Salamanca, Spain

05:05 PM
How do I Treat Higher Risk MDS?

TC

Thomas Cluzeau, MD
Nice University Hospital Center, France

05:25 PM
How do I Treat CMML?

DW

Daniel Wiseman, MD
The Christie NHS Foundation Trust, Manchester, UK

05:45 PM
Panel Discussion
06:05 PM
Coffee Break

Session IX: Unique topics in MDS
Moderated by: TBD

06:25 PM
Sequencing Therapies in Lower Risk MDS

MDP

Matteo Della Porta, MD
Humanitas University, Milan, Italy

06:45 PM
Addressing Optimal Symptom Management in MPN in Clinical Practice

RK

Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL

07:05 PM
Treatment Endpoints for CML in 2026

CG

Carmelo Gurnari, MD
University of Rome Tor Vergata, Rome, Italy

07:25 PM
Panel Discussion
07:45 PM
Adjourn

Ben Whitley
Project Manager

How long has Ben Whitley been in the business?

Ben Whitley has been with MD Education since 2025.

About Ben Whitley

As a Project Manager, I support the successful delivery of projects on time and within scope. I bring strong skills in project tracking, documentation management, and confident stakeholder engagement, and I take great pride in being part of a collaborative team. With a background in Business and IT, I apply this combined knowledge to streamline processes and support efficient project delivery. I value opportunities to meet and network with new people, enabling me to build and maintain strong professional relationships.

Ben-Whitley-web